Eric Lo, MD
Cardiovascular Disease · Dunn, NCNPI 1497782023
Payments from drug & device makers
What this record shows
28 manufacturers reported payments, led by Penumbra, Inc. at 30.6% of the total. Reporting peaked in 2022 at $3,640 and has fallen 65.4% since, to $1,258 in 2025.
Across 159 payments — averaging $69.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Abbott$2K
- Medtronic$1K
- Cardiovascular Systems Inc.$1K
- Boston Scientific$714
- Philips North America LLC$648
- plus $2K from 22 others
Across 7 payments — averaging $8291.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$53K
- Boehringer Ingelheim$5K
What the payments were for
- Travel & lodging$5,58651%
- Food & beverage$5,39149%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 5 | $3,357 |
| Abbott | 20 | $1,943 |
| Medtronic | 26 | $1,419 |
| Cardiovascular Systems Inc. | 12 | $1,075 |
| Boston Scientific | 21 | $714 |
| Philips North America LLC | 5 | $648 |
| Biotronik Inc. | 6 | $431 |
| Abiomed | 2 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $173 |
| Biosense Webster, Inc. | 7 | $172 |
| Atricure, Inc. | 6 | $140 |
| Amgen | 5 | $129 |
| E.r. Squibb & Sons, L.L.C. | 6 | $83 |
| Merck | 3 | $65 |
| Boehringer Ingelheim | 2 | $54 |
| Cvrx, Inc. | 3 | $47 |
| Novo Nordisk | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| Johnson & Johnson | 3 | $40 |
| Ascensia Diabetes Care US Inc. | 1 | $37 |
| Teleflex LLC | 1 | $29 |
| Bayer | 2 | $29 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| AstraZeneca | 2 | $27 |
| Pfizer | 2 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Novartis | 1 | $14 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,967
- Diamondback Peripheral$1,674
- Indigo$1,390
- RESOLUTE ONYX$679
- AVEIR$466
- IV Other$356
- COREVALVE EVOLUT R$295
- (9520) IGT Devices Undivided$242
- BioMonitor$142
- Impella$121
- GENERAL TACHY$119
- JOT DX$107
How this compares
$10,976 in reported general payments places this provider in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $42,710 |
| EntrestoSacubitril/Valsartan | 22 | $19,231 |
| XareltoRivaroxaban | 11 | $17,169 |
| JardianceEmpagliflozin | 14 | $12,625 |
| Metoprolol Succinate | 68 | $820 |
| ClopidogrelClopidogrel Bisulfate | 27 | $422 |
| Atorvastatin Calcium | 29 | $218 |
| Spironolactone | 20 | $136 |
| Rosuvastatin Calcium | 15 | $124 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $88 |
| Losartan Potassium | 12 | $69 |
| Amlodipine Besylate | 23 | $50 |
| Furosemide | 15 | $50 |
| Atenolol | 11 | $34 |
| Lisinopril | 21 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $42,71055 claims |
| NovartisEntresto | $14 | $19,23122 claims |
| Johnson & JohnsonXarelto | $40 | $17,16911 claims |
| Boehringer IngelheimJardiance | $54 | $12,62514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Dunn
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.